Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences EW after attending the Transcatheter Valve Therapies meeting.
In a research report published today, Piper Jaffray states, "We expect FDA approval of EW's transcatheter valve system yet this
year (mid-October is our point estimate). Despite more balanced clinical data, our
view from the TVT meeting is that transcatheter valves are still going strong in
Europe, demand in the US even for the initial indications will be high, and the
development of a strong new medtech business continues unabated."
At the moment, Piper Jaffray has a price target of $94 placed on the company's stock. On Wednesday, Edwards Lifesciences lost 0.61% of its value to close the day at $85.94.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsEdwards LifesciencesHealth CareHealth Care EquipmentPiper Jaffray
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in